MDxHealth SA (NASDAQ:MDXH) Receives $2.83 Average PT from Brokerages

MDxHealth SA (NASDAQ:MDXH) has received a consensus rating of “Hold” from the five research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $2.1667.

A number of equities research analysts have recently commented on MDXH shares. TD Cowen reissued a “buy” rating and issued a $1.50 target price (down from $7.00) on shares of MDxHealth in a research note on Thursday, May 14th. Lake Street Capital set a $3.00 price target on shares of MDxHealth and gave the stock a “buy” rating in a research note on Friday, August 14th. BTIG Research cut their price objective on shares of MDxHealth from $4.00 to $2.00 and set a “buy” rating on the stock in a research report on Friday. William Blair downgraded shares of MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Finally, Wall Street Zen upgraded shares of MDxHealth to a “sell” rating in a research note on Saturday, August 15th.

Institutional Investors Weigh In On MDxHealth

A number of institutional investors have recently made changes to their positions in the company. Intesa Sanpaolo Wealth Management purchased a new position in MDxHealth in the 4th quarter worth approximately $36,000. Lido Advisors LLC purchased a new stake in MDxHealth during the 3rd quarter valued at $48,000. Squarepoint Ops LLC purchased a new stake in MDxHealth during the 4th quarter valued at $51,000. Jefferies Financial Group Inc. bought a new stake in shares of MDxHealth in the 3rd quarter worth $53,000. Finally, Balyasny Asset Management L.P. bought a new stake in shares of MDxHealth in the 4th quarter worth $68,000.

MDxHealth Stock Up 3.2%

MDxHealth stock opened at $0.74 on Friday. The company has a market capitalization of $36.78 million, a P/E ratio of -1.03 and a beta of 1.42. The stock’s 50 day moving average is $0.50 and its 200 day moving average is $1.68. MDxHealth has a twelve month low of $0.40 and a twelve month high of $5.33.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. The company had revenue of $27.21 million for the quarter, compared to the consensus estimate of $26.14 million. As a group, equities analysts expect that MDxHealth will post -0.49 EPS for the current year.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.